Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molibresib and Entinostat in Advanced Solid Tumors and Lymphomas
NCT03925428Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Sep 2020
- Primary completion
- Sep 2020
- Modality
- Allosteric Modulators
01
Overview
Phase 1, open-label, single-arm trial of molibresib and entinostat in solid tumor, lymphoma and pancreatic cancer (PC), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Sep 2020; status: withdrawn.
02
Drugs
molibresibentinostat
03
Conditions
solid tumorlymphomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03925428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925428.